Drug intelligence / Profile preview

IK-5f

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal Injection

Overview

IK-5f is a novel small-molecule compound identified for its potential in treating Alzheimer's disease (AD). It functions by significantly inhibiting the aggregation of amyloid-beta (Aβ) and promoting the dissociation of Aβ fibrils in vitro. Preclinical studies in 5XFAD mice demonstrated that IK-5f improved cognitive performance, reduced hippocampal Aβ plaque burden, and decreased neuroinflammation, suggesting its efficacy in mitigating AD pathology.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on IK-5f.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IK-5f.

Explore the full profile